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Abstract
Cytomegalovirus (CMV) has been implicated as a factor in immunosenescence, including poor 
antibody response to vaccination and higher immune activation and inflammation. Some people 
may be more or less vulnerable to the negative effects of CMV. The present investigation tested the 
effects of beta-blocker use and chronological age on the associations between CMV and immunity 
in adults aged 60–91 (N=98; 69% CMV seropositive) who were administered the trivalent 
influenza vaccine for up to 5 years. Peak antibody response, corrected for baseline, and spring 
(persistent) antibody response, corrected for peak, were assessed, as well as beta-2 microglobulin 
(β2μ) and interleukin-6 (IL-6). In multi-level models with years at Level 1 and people at Level 2, 
CMV serostatus did not predict peak antibody response, but there was a 3-way interaction between 
CMV serostatus, age, and beta-blockers. Age was negatively associated with peak antibody, but 
only among adults who were CMV seropositive and taking beta-blockers. CMV seronegative 
adults who were not taking beta-blockers had the highest antibody persistence. CMV serostatus 
was not associated with β2μ or IL-6. Results suggest that CMV+ serostatus may negatively 
compromise antibody response to a greater degree than inflammatory markers in older adults. 
Furthermore, older adults who take beta-blockers may be more vulnerable to negative effects of 
age and CMV on peak antibody response, perhaps by virtue of their underlying health condition.
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1. Introduction
Cytomegalovirus (CMV) is an epidemic latent herpesvirus with age-related prevalence, 
ranging from 40% (18–24 years old) to over 90% (75–80 years old) (Badami et al., 2009). 
Unlike other herpesviruses, CMV is rarely associated with a symptomatic acute infection in 
immunocompetent hosts. It has been suggested that CMV co-evolved with its hosts, 
resulting in a relatively benign infection (Britt, 2008). However, CMV is not entirely benign. 
Latent CMV infection may have consequences for the aging immune system, as CMV is 
thought to drive immune senescence (Koch et al., 2007). Consequences include a high 
percentage of senescent T (CD8+CD28− or CD8+CD57+) and natural killer (NK; 
CD56dimCD57+) cells in blood (Lopez-Vergès et al., 2011; Olsson et al., 2001; Wang, 
Taylor-Wiedeman, Perera, Fisher, & Borysiewicz, 1993). The cytokine profile of senescent 
cells is more proinflammatory than non-senescent cells (Effros, 2012; Effros, Dagrarag, 
Spaulding, & Man, 2005). CMV antibody titers correlate with proinflammatory cytokines in 
serum, as well as monocyte activation (de Pablo-Bernal et al., 2015; Trzonkowski et al., 
2003). Ultimately, enhanced “inflammaging” due to CMV could increase risk for multiple 
health problems of older adulthood (Ershler & Keller, 2000; Frasca & Blomberg, 2016). 
Importantly, senescence-associated immune changes have also been framed as immune 
adaptation, such that the sustained inflammatory state of older adults’ innate immune system 
may be the necessary prerequisite for an acceptable level of functioning of the adaptive 
immune response (Fulop et al., 2016). Nevertheless, the absolute number of senescent cells 
is so much increased that they themselves may cause pathology as a result of their higher 
ability to produce inflammatory mediators (Pawelec, Larbi, & Derhovanessian, 2010).
CMV may also contribute to poor antibody production by B cells (Simons & Reynolds, 
1990). CMV antibody titers correlated negatively with antibody response to influenza 
vaccination among both older (65–99 years) and younger (19–40 years) adults (Trzonkowski 
et al., 2003). However, in another sample of older (62–89 years) and younger (20–30 years) 
adults, CMV+ serostatus was associated with more antibody production after vaccination 
among younger adults but not among older adults (Furman et al., 2015). Among older (77–
88 years) long-term care residents (den Elzen et al., 2011) and adults aged 69 years 
(Strindhall et al., 2016), CMV+ serostatus was unrelated to vaccine antibody responses. 
Differences between older and younger adults in the effects of latent CMV infection on 
antibody response to vaccine may be a consequence of duration of latent infection (Furman 
et al., 2015) or of an interactive effect with chronological age.
These varying relationships between CMV and antibody response to vaccination among 
older adults suggest the existence of factors that make individuals more or less susceptible to 
effects of latent CMV infection. One such factor is activation of the sympathetic nervous 
system. Stress-induced catecholamines stimulate CMV gene expression via the β2-
adrenergic receptor (β2AR) (Prösch et al., 2000). Mental and physical stressors can induce 
latent herpes simplex virus reactivation via neuroendocrine factors, including 
catecholamines (Freeman, Sheridan, Bonneau, & Hendricks, 2007). Treatment with 
propranolol, a β-adrenergic receptor blocker, reduced herpes simplex virus type 1 
reactivation in an animal model (Gebhardt & Kaufman, 1995). In vitro, propranolol 
abrogated the stimulatory effect of epinephrine and norepinephrine on human CMV activity 
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(Prösch et al., 2000). Thus, for older adults infected with CMV, beta-blockers may be 
protective against CMV-induced immune dysregulation (i.e., lower antibody titers to 
vaccination and higher inflammation) insofar as blockade of the β2AR may prevent CMV 
reactivation.
However, beta-blockers may also interfere with sympathetically induced expression of 
costimulatory molecules (e.g., B7-2) on B cells and exert timing-dependent suppression of B 
cell antibody responses (Sanders, Kasprowicz, Kohm, & Swanson, 2001). In the present 
sample of older adults, beta-blockers correlated with less antibody production in the month 
after influenza vaccination (Segerstrom, Hardy, Evans, & Greenberg, 2012). However, that 
analysis did not consider CMV serostatus or longer-term antibody persistence.
The present study therefore tested the effects of chronological age, CMV serostatus, and 
beta-blocker use among older adults on two aspects of immunosenescence: antibody 
production after influenza vaccination and markers of immune activation and inflammation 
(beta-2 microglobulin [β2μ] and interleukin-6 [IL-6]). We focused on β2μ and IL-6 because 
they are found in higher levels in healthy older compared with younger adults (Dong et al., 
2016; Forsey et al., 2003), are related to clinically relevant health outcomes in older adults, 
including frailty and age-related cognitive dysfunction (Cohen, Harris, & Pieper, 2003; 
Smith et al., 2015), and one is produced by both immunocytes and adipose tissue (IL-6; 
O’Connor et al., 2009), whereas the other (β2μ) is produced by immunocytes. The first 
hypothesis was that older age and CMV+ serostatus would correlate with lower antibody 
production after vaccination and higher levels of β2μ and IL-6 (Frasca & Blomberg, 2016). 
The second hypothesis was that beta-blockers would blunt the effects of CMV on antibody 
production and inflammatory markers. However, because beta blockade may have also 
adverse effects on antibody production in earlier stages of B cell activation and maturation 
(Sanders et al., 2001; Segerstrom et al., 2012), exploratory analyses tested these hypotheses 
both with regard to antibody production in the short term (i.e., weeks after vaccination) and 
antibody persistence in the long term (i.e., months after vaccination).
2. Materials and methods
2.1 Participants
Participants were 98 older adults recruited through the clinics and volunteer subject pool of 
the Sanders-Brown Center on Aging and administered the trivalent influenza vaccine for up 
to 5 years (n=325 person-years; see Table 1). The sample was on average 74 years old at 
enrollment (range = 60–91). The majority were female (62%), Caucasian (95%), and CMV 
seropositive (69%).
2.2 Procedures
All procedures were approved by the University of Kentucky Institutional Review Board. 
Participants were recruited continuously from 2001 to 2007. Those older adults who had 
expressed interest in research participation to the Center on Aging were contacted by phone 
and screened. Inclusion criteria were: age 60 or older, married, and willing to be vaccinated 
against influenza. Exclusion criteria were: diseases that affect the immune system (e.g., 
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autoimmune disease, cancer); chemotherapy or radiation in the 5 years prior to enrollment; 
immunomodulatory medications including opioids and steroids; or more than two of the 
following classes of medications: psychotropics, anti-hypertensives, hormone replacement, 
or thyroid supplements. These criteria excluded major influences on immune responses and 
allowed reasonably healthy adults to participate in the study.
Participants were interviewed semi-annually in their homes and provided a list of current 
medications at each visit. Vaccinations were performed annually from 2001 to 2008. Nurses 
administered the commercially available, seasonal, trivalent influenza vaccine in the 
participant’s home or in the clinic, whichever the participant preferred. Blood draws were 
taken immediately before vaccination, 2 and 4 weeks after vaccination, and in the spring 
following vaccination (late March to early April; M=170.8 days after vaccination, SD 
=13.8).
2.3 Measures
2.3.1 Demographics and medications—Subjects reported their date of birth (used to 
calculate age at each wave); gender; and height and weight (used to calculate body mass 
index [BMI]) at their first semi-annual visit. Beta-blocker and statin use at each visit was 
coded by a study nurse from participants’ medication lists. Blood draws were matched to 
medication lists from the interview closest in time. Beta-blocker and statin use were both 
treated as time-varying variables. However, most participants were on consistent 
medications throughout the study period: 68.3% consistently off beta-blockers and 19.2% 
consistently on beta-blockers; 43.3% consistently off statins and 28.0% consistently on 
statins.
Of those individuals on beta-blockers, 52% (n=12) were on generic metoprolol, 13% (n=3) 
were each on atenolol, carvediolol, and propranolol, and 4% (n=1) were each on acebutolol 
and bisoprolol. The majority of individuals on metoprolol (n= 11) and all individuals on 
propranolol (n= 3) were CMV seropositive; the CMV serostatus of individuals on the each 
of the remaining beta-blockers (atenolol, carvediolol, acebutolol, bisoprolol) were roughly 
split between seropositive and seronegative. The average dosage per day was 50 mg (SD = 
66, median = 25, mode = 50, range = 3.125 – 400). The majority (47%) were on beta-
blockers to treat high blood pressure, and the remaining were either on beta-blockers for 
arrhythmias (29%) or did not know or did not report why they were on beta-blockers (24%).
2.3.2 Cytomegalovirus (CMV) serostatus—CMV IgG titers were assessed by enzyme 
immunoassay in a single batch (EIA-1797, DRG International, Inc.). Median inter-assay CV 
was 2.8 (range = 0.1 – 10.2) and median intra-assay CV was 3.4 (range = 1.8 – 7.5). The 
first and last archived longitudinal samples from each participant were assayed. Seronegative 
status was defined as titer < 1 IU/ml; seropositive status was defined as titer > 1 IU/ml in 
both samples and ≥ 10 IU/ml in at least 1 sample. Two participants were eliminated from 
analysis because they seroconverted during the study.
2.3.3 Antibody response: Peak and persistence—Antibody titers against the H1N1, 
H3N2, and B vaccine components were assayed separately by hemagglutination inhibition 
tests. Specific vaccine strains included the following (WHO, 2016): H1N1 (2001–2007: 
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A/New Caledonia/20/99; 2007–2008: A/Solomon Islands/3/2006), H3N2 (2001–2004: A/
Moscow/10/99; 2004–2005: A/Fujian/411/2002; 2005–2006: A/California/7/2004; 2006–
2008: A/Wisconsin/67/2005), and B (2001–2002: B/Sichuan/379/99; 2002–2004: B/
HongKong/330/2001; 2004–2006: B/Shanghai/361/2002; 2006–2008: B/Malaysia/
2506/2004). Two antibody responses were examined: peak and persistent responses. Peak 
antibody was defined as the higher of the 2-week or 4-week post-vaccine titers. Antibody 
persistence was the spring titer. Characterization of the antibody responses in this sample 
has been previously described (Segerstrom et al., 2012). All antibody titers were 
standardized within specific vaccine formulation (e.g., A/New Caledonia/20/99) and then 
within strain (H1N1). Because all subjects had previously been vaccinated against influenza, 
and antibody response following vaccination in a partially seropositive sample depends 
highly on prior antibody levels, peak antibody response was corrected for baseline antibody 
level, and persistence was corrected for peak response (Beyer et al., 2004). All corrected 
antibody titers were reasonably correlated with each other within year (H1N1 with H3N2 
was r =.45; H1N1 with B was r =.40; H3N2 with B was r =.30). Thus, the strain-specific 
vaccine titers were averaged to create reliable composites of peak response (α=.64) and 
persistence (α=.58) that were used in all analyses. Higher scores represent larger antibody 
responses. There was evidence of flu infection at two person-year observations, indexed by 
the serological criterion of a fourfold increase from peak to persistent raw antibody titers. 
Thus, the persistent antibody titers for those two person-year observations were not included 
in the standardization of antibody titers or in further analyses.
2.3.4 Inflammatory markers: β2μ and IL-6—β2μ and IL-6 were collected in serum. 
The present analysis used samples collected before influenza vaccination and approximately 
6 months later. β2μ was assayed using enzyme linked immunosorbent assay (ELISA; 
ALPCO Diagnostics). Median inter-assay CV was 3.8 (range = 2.8 – 4.7) and median intra-
assay CV was 2.3 (range = 1.3 – 3.1). IL-6 was assayed with high-sensitivity ELISA (R & D 
Systems). Median inter-assay CV across the study period was 6.44 (range = 3.1–13.3) and 
median intra-assay CV was 2.17 (range = 1.4–3.7). IL-6 was subjected to a log10 
transformation to improve normality; the distribution of β2μ did not require transformation. 
Inflammatory marker data for waves at which individuals were currently suffering from 
acute infection (n=12) were removed prior to analyses.
2.4 Statistical Analyses
Table 2 presents descriptive information for study variables. Data were analyzed in 
multilevel models to account for the repeated measures (i.e., years, Level 1) nested within 
individuals (Level 2). We implemented models in SAS PROC MIXED using maximum 
likelihood estimation, Kenward-Roger degrees of freedom, and an unstructured matrix for 
the random components (Singer, 2002). These models use all available data without the need 
for either list-wise deletion or data imputation (Singer & Willett, 2003).
Null models with no predictors were used to estimate the intraclass correlations (ICC) for 
the four outcomes: peak antibody response, persistent antibody response, β2μ, and IL-6. 
Subsequent models included age at each wave (centered around 74, the sample mean age at 
study entry), beta-blocker use, and CMV serostatus as main effects. Given that adipose 
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tissue produces proinflammatory cytokines (O’Connor et al., 2009), models predicting IL-6 
also controlled for BMI (grand mean centered). Models predicting IL-6 and β2μ also 
controlled for statin use, given potential anti-inflammatory effects (O’Connor et al., 2009). 
Separate models tested main effects of and interactions between age, beta-blockers, and 
CMV serostatus on antibody responses (peak and persistence), β2μ, and IL-6. Models were 
run separately for each outcome variable. Following methods outlined by Aiken and West 
(1991), significant interactions were probed at meaningful levels of chronological age (60, 
70, 80, and 90 years of age), beta-blocker use, and CMV serostatus.
3. Results
3.1 Available Data
The percentages of missing person-year observations for peak and persistent antibody 
responses and inflammatory markers were each between 22–26%. The number of available 
data points for peak and persistent antibody responses did not differ across CMV serostatus 
(peak: t(96)=−1.68, p=.10; persistent: t(96)=−1.24, p=.22) nor beta-blocker use (peak: 
t(96)=.50, p=.52; persistent: t(96)=.32, p=.75). In addition, the number of available data 
points for peak and persistent antibody responses did not correlate with age (peak: r= −.02; 
persistent: r= −.02).
3.2 Longitudinal Structure of Antibody Responses and Inflammation: Stability and Change
Intraclass correlations from multilevel models with years at Level 1 and people at Level 2 
indicated a minority of the variance in antibody response was due to stable between-person 
differences (27% of peak; 38% of persistence), and a majority was due to within-person 
changes between years (73% of peak; 62% of persistence). Conversely, a majority of the 
variance in β2μ was due to between-person differences (73%), and a minority was due to 
within-person changes (27%). The variance in IL-6 was more evenly split between between-
person differences (43%) and within-person changes (57%).
3.3 Peak Antibody Response
There were no main effects of chronological age, beta-blocker use, or CMV serostatus on 
peak antibody response. There was, however, a significant 3-way interaction between 
chronological age, beta-blocker use, and CMV serostatus predicting peak antibody response 
(γ = −.13, SE = .05, t(187) = −2.19, p=.030). As shown in Figure 1, age was negatively 
associated with peak antibody production, but only among adults who were CMV 
seropositive and taking beta-blockers (simple age slope: γ = − .08, SE=.02, p <.0001).
3.4 Spring Antibody Persistence
Chronological age did not significantly predict antibody persistence, controlling for peak 
antibody. As predicted, CMV seropositive adults had less antibody persistence (main effect: 
γ = −.35, SE=.14, p =.013), and use of beta-blockers was also associated with less 
persistence (main effect: γ = −.50, SE=.25, p=.044). CMV serostatus and beta-blocker use 
were, however, qualified by a statistically significant interaction between them (interaction: 
γ = .57, SE = .28, t(194)=2.01, p =.046). As shown in Figure 2, CMV- adults who were not 
taking beta-blockers had the highest antibody persistence (estimate = .25): significantly 
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higher than both CMV- adults taking beta-blockers (estimate = −.31; simple main effect: γ = 
−.46, SE =.21, p=.032) and CMV+ adults not taking beta-blockers (estimate = −.08; simple 
main effect: γ = −.33, SE =.12, p=.006). CMV+ adults had similar antibody persistence 
whether or not they were taking beta-blockers (simple main effect: γ = .07, SE =.15, p=.62).
3.5 Inflammatory Markers: β2μ and IL-6
Older chronological age was associated with higher β2μ (γ =.017, SE=.008, t(90.3)=2.12, 
p=.037) and IL-6 (γ =.023, SE=.009, t(127)=2.38, p=.019). Beta blocker use was also 
associated with higher β2μ (γ =.35, SE=.105, t(86.9)=3.36, p=.001) and IL-6 (γ =.28, SE=.
121, t(121)=2.31, p=.023). There was no main effect of CMV, or interactions with age or 
beta-blocker use, on β2μ or IL-6.
4. Discussion
The present study tested the effect of CMV serostatus, as well as its interactions with 
chronological age and beta blockade, on antibody responses to influenza vaccination and 
markers of immune activation (β2μ) and inflammation (IL-6) in healthy older adults. Results 
partially supported our hypotheses. Individuals who were CMV seropositive had poorer 
antibody persistence, although not poorer peak antibody. When the combinations of CMV 
serostatus, age, and beta blockade were considered, individuals who were CMV seropositive 
and who were taking beta-blockers were more susceptible to age-related decline in peak 
antibody. Contrary to predictions, CMV was not associated with β2μ or IL-6 either by itself 
or in combination with age and beta blockade. The results implicate CMV in aspects of 
immunosenescence centered more on B cell function, especially memory function, than on 
immune activation and inflammatory markers in this sample of healthy, older adults.
CMV+ serostatus was not associated with peak antibody response per se, but was associated 
with poorer antibody persistence. Others have reported no association between CMV 
serostatus and peak antibody response (Furman et al. 2015; Strindhall et al., 2016; Wald et 
al. 2013). However, these studies have not examined the effect of CMV serostatus on 
antibody persistence through the end of influenza season. Antibody persistence may 
contribute to clinical protection for over 6 months post-vaccination (Skowronski, Tweed,& 
De Serres, 2008), with one recent report suggesting protection through at least one 
subsequent influenza season (i.e., 1.5 years post-vaccination; Sridhar et al., 2015); thus, 
persistence is an equally important aspect of the antibody response to investigate. Peak 
antibody after vaccination depends mainly on short-lived plasma B cells, whereas antibody 
persistence depends on CD27+ memory B cells and long-lived plasma cells. The number of 
memory B cells after vaccination correlated with antibody persistence for both pertussis and 
measles (Buisman, de Rond, Öztürk, ten Hulscher, & van Binnendijk, 2009). CMV+ 
serostatus was negatively associated with predictive biomarkers of vaccine responses, 
including switched memory B cells (Frasca et al., 2015). T cell help is thought to be 
important for B cell memory; therefore, effects of CMV on the memory T cell population 
may account for its adverse effects on antibody persistence after vaccination (McHeyzer-
Williams & McHeyzer-Williams, 2007; Olsson et al., 2001).
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In the current study, markers of immune activation (β2μ) and inflammation (IL-6) were 
higher with older age, but CMV+ serostatus was not associated with β2μ or IL-6. This 
finding is contrary to previous research suggesting that CMV is positively associated with 
proinflammatory cytokine release, or “inflammaging”, in older adults (Trzonkowski et al., 
2003; van de Berg et al., 2010). However, in a recent 10-year longitudinal study of older 
adults, levels of proinflammatory cytokines increased over time independently of CMV 
serostatus (Bartlett et al., 2012). Another possibility is that inflammatory markers correlate 
with the length of time that an individual has been CMV seropositive or the degree of CMV 
activation, as opposed to serostatus (Bosch et al., 2013). Furthermore, inflammaging may 
not be reducible to a single cause (e.g., CMV) but rather the additive or synergistic effects of 
other chronic infections and diseases that can often take place simultaneously in older adults 
(Salvioli et al., 2013).
Based on previous research indicating that sympathetic nervous system activity may 
facilitate latent virus reactivation via costimulatory molecules on B-cells (Prösch et al., 
2000), we predicted that beta-blockers would have an anti-viral and anti-inflammatory effect 
(Gebhardt & Kaufman, 1995; Ohtsuka et al., 2001) and facilitate more desirable immune 
outcomes in CMV seropositive adults. However, older adults taking beta-blockers were more 
vulnerable to the effects of CMV and age on peak antibody response. Additionally, CMV 
seronegative adults taking beta-blockers had significantly less antibody persistence than 
those not taking beta-blockers, although this effect requires replication given the small 
number of people in the CMV−/BB+ subset of the present sample (see Table 1). Beta 
blockade was also positively associated with β2μ and IL-6. In the present sample, 
participants were not randomized to beta blockade, and its effects may have more to do with 
underlying pathophysiology (e.g., hypertension) than CMV reactivation. Older adults 
prescribed beta blockers may also have genetic, metabolic, or behavioral qualities associated 
with immune activation (Perk et al., 2012). To test this interpretation, we examined post hoc 
the relationship between beta blockade and general health as reflected in self-rated health 
(1= excellent, 5 = poor) and the Chronic Disease Score (Clark et al., 1995). Controlling for 
age and CMV status in multilevel models, taking beta-blockers was associated with poorer 
self-rated health (2.51 vs. 2.23, t(307) =2.20, p =.03) and higher Chronic Disease Score 
(1360 vs. 942, t(309) = 7.66, p < .0001). Therefore, beta blockade may index poor health in 
the present study. The findings suggest a need for experimental designs randomizing 
participants to beta blockade to tease apart effects of the actual drug versus underlying 
health conditions on aspects of immunosenescence. In addition, it may be that the 
therapeutic effect of beta blockade is conferred through long-term use; however, this remains 
an open question in subjects without cardiac issues. The availability of pre-clinical data and 
approved, safe, and inexpensive beta-antagonists with well-understood pharmacology and 
minimal side effects provide a favorable risk/benefit profile for clinical testing of beta 
blockade (Baker, Hill, & Summers, 2011). Previous experimental designs have tested 
shorter-term beta blockade (in patients without confounding indication of cardiovascular 
issues) as an effective therapeutic in, for example, clinical oncology for cancer cachexia and 
immune outcomes in the perioperative period of breast cancer surgery (Stewart Coats et al., 
2016; Zhou et al., 2016).
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The findings also call for additional research into the interaction of CMV with other, non-
immune health risks such as mood (depression, anxiety; Phillips, Carroll, Khan, & Moss, 
2008) or hypertension (Firth et al., 2016) in the promotion of immune senescence. In the 
present sample, individuals without either CMV or beta-blockers had the best antibody 
persistence. Likewise, individuals in this sample without either psychological distress or 
poor physical condition (sedentariness or high BMI) had the best peak antibody response 
(Segerstrom et al., 2012, Figures 2 and 3). Therefore, in this sample of older adults, 
interactions between risk factors took a form in which having a single risk factor was 
sufficient to compromise antibody responses to vaccination, and having two risk factors was 
not significantly worse than either one alone. Targeting a single risk factor, whether that be 
latent virus infection, comorbid health conditions, psychological distress, or health behavior, 
may not be sufficient to improve response to vaccination in older adults.
We cannot draw conclusions about the protective effects of the antibody titers in the current 
study as it is unknown if exposure to influenza may result in effective clinical immune 
responses. However, lower antibody titers may translate to poorer clinical outcomes upon 
exposure to influenza (Ohmit, Petrie, Cross, Johnson, & Monto, 2011). In addition, these 
findings do have clinical implications for naturalistic interactions between beta blockade, 
CMV serostatus, and response to vaccination. Given the high prevalence of medication use 
among older adults (Qato et al., 2008), consideration of the effects of beta blockade on 
markers of immunosenescence is important. Although influenza vaccination prevents 
hospitalizations and deaths in older adults (Darvishian et al., 2014), those who mount a 
smaller antibody peak response to the vaccination may be at higher risk. Thus, beta blockers 
may not be an effective influenza vaccine adjuvant in CMV seropositive older adults when 
taken therapeutically for health conditions such as hypertension.
One limitation of the current research was the operationalization of CMV as serostatus 
rather than titers. A well-controlled CMV infection is likely to have different effects than 
one that is poorly controlled and, indeed, in previous studies, CMV antibody titers correlated 
with peak antibody response after influenza vaccination where serostatus did not (den Elzen 
et al., 2011; Furman et al., 2015; Trzonkowski et al., 2003). CMV antibody titers also 
correlated with markers of immune activation (de Pablo-Bernal et al., 2015; Trzonkowski et 
al., 2003). The age of the archived samples in the present study (dating back to 2001) 
suggested that serostatus could be more reliably measured than antibody titer; however, 
future research should examine both CMV serostatus and titers. It is also unknown when 
older adults in the current sample first contracted CMV. How long the host immune system 
has been working to “control” the latent virus could have differential effects on 
immunosenescence (Bosch et al., 2013). In addition, CMV was the only latent viral infection 
examined. Others (e.g., Epstein-Barr virus) are also common in older adults and may further 
impact immune function and health. For example, an aggregate index of latent infections 
correlated with cognitive function in young and middle adulthood (Gale, Erickson, Berrett, 
Brown, & Hedges, 2016), and such an index may have more predictive power for immune 
senescence than a single infection. Finally, markers of B and T cell function were not 
directly assessed in the current study, but may explain part of the effects of CMV on 
antibody responses.
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These findings contribute to a growing body of research demonstrating the role of CMV on 
immune senescence. To our knowledge, this is the first study that has examined the joint 
effects of beta blockade and CMV serostatus on antibody responses and inflammation in 
older adults. Older adults with CMV who are also taking beta-blockers in a naturalistic 
context may be more vulnerable to negative effects of age on peak antibody response. These 
effects may differ from experimental beta blockade and suggest continued exploration of the 
contexts in which CMV affects immunosenescence in older adults.
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Highlights
• Beta-blocker (BB) use and age may affect associations between CMV and 
immunity.
• In CMV+BB+ adults, age was negatively associated with short term antibody 
response.
• CMV−BB− adults had the highest antibody persistence in the long term.
• CMV serostatus was not associated with beta-2 microglobulin or 
interleukin-6.
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Figure 1. 
Peak antibody simple slopes from decomposition of the interaction among chronological 
age, beta-blocker use (on +/ off −), and CMV serostatus (seropositive +/seronegative −). 
Peak antibody titers are in approximate Z units, or the number of standard deviations from 
the mean = 0. Error bars represent standard errors of the estimates.
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Figure 2. 
Antibody persistence model estimates with p values from simple main effect decomposition 
of the interaction between CMV serostatus (seronegative − /seropositive +) and beta-blocker 
use (on + /off −). Each bar represents the estimated spring antibody titer (in approximate Z 
units, or the number of standard deviations from the mean = 0) for each combination of 
CMV serostatus and beta-blocker use. Each bar starts at 0 and extends to the approximate Z 
unit for the designated combination. Error bars represent standard errors of the estimates.
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Table 1
Number of people, person-year observations, and mean ages at CMV/Beta Blockade combinations
CMV seronegative CMV seropositive Total
BB − N=24, PY= 74AgeM = 75
N= 51, PY =182
AgeM = 75
N= 75, PY=256
BB + N=6, PY =15AgeM = 76
N=17, PY= 54
AgeM = 77 N= 23, PY=69
Total N = 30, PY=89 N= 68, PY= 236 N= 89, PY=325
Note. N = number of people; PY = number of person-year observations; BB = Beta-blocker use, indicated by off − / on +. Although beta-blocker 
use was time-varying, for the purposes of this table, the n = 7 individuals who were more often off beta-blockers than on are represented as “off”, 
and the n = 5 individuals who were more often on beta-blockers than off are represented as “on”.
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